AlphAIAlphAI — Financial news for AI agents
SEC EDGARSEP 101 min read$RXRX

Khan Najat sold $79K of RXRX

Khan Najat (CEO and President) sold 22,408 shares of RECURSION PHARMACEUTICALS, INC. (RXRX) at $3.52 on 2026-09-08 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Khan Najat
Published Sep 10, 2026, 9:55 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 10, 2026, 9:57 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$RXRX
Neutral
medium confidence
Mentioned
$RXRX
Relevance
2/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$RXRXNeutralLow
01

Why it matters

The CEO's sale is modest and unlikely to move the stock, but it provides transparency for investors.

02

Market read

Primary disclosure of a small insider sale; limited trading relevance.

03

What to watch

Potential tax planning or diversification motives not disclosed.

Relevance 2/10Novelty 3/10Timing: post‑market filing on 2026‑09‑10

Background

Form 4 filing discloses insider transactions required by SEC regulations.

Company-level read

Ticker impact

$RXRXNeutralMedium confidence
Context

CEO Khan Najat sold 22,408 shares for $78,822.38 via a 10b5‑1 plan on 2026‑09‑08.

Expected impact

Minimal short‑term impact; price likely unchanged or slightly down.

Evidence & confidence

The sale size ($79K) is small relative to the insider's remaining holdings (2.07M shares) and typical market volume, so market reaction is expected to be limited.

Market effects

Sector

No immediate sector impact; biotech sector remains unchanged.

Regional

Limited to US biotech investors.

Global

Low global relevance.

Counterpoint

What could challenge this read

The sale could be a routine liquidity move, not a negative signal.

Key entities

  • Executive
    Khan Najat

    CEO and President of Recursion Pharmaceuticals.

  • Company
    Recursion Pharmaceuticals, Inc.

    Biotech firm listed on NASDAQ under ticker RXRX.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

RXRX insider trading history →

Related articles

OCT 19
$RXRXHighAI 8/10

RXRX Stock Pops As Sanofi Deal And ARK Buying Fuel AI-Drug Hype

Recursion Pharmaceuticals (RXRX) stock rose 4.26% on optimism over AI-driven drug advances. The company reported positive Phase 1b/2 trial results for REC-4881 and early Phase 1 data for REC-1245. Sanofi optioned a candidate, triggering a $10M milestone. RXRX raised $200M, extending its cash runway. The stock has high volatility, trading at a 43x P/S ratio with negative margins.

timothysykes.com3 min
OCT 19
$RXRXHighAI 8/10

RXRX Stock Pops As Sanofi Deal, ARK Buying Fuel AI Biotech Story

Recursion Pharmaceuticals Inc. (RXRX) stock rose 3.85% on AI-driven drug discovery progress and institutional buying. The company reported positive Phase 1b/2 data for REC-4881 and REC-1245, and Sanofi exercised an option on an inflammatory candidate, triggering a $10M milestone. RXRX raised $200M in a follow-on offering, and ARK Investment Management has been accumulating shares. The company has no near-term profits but has a strong cash position and strategic partnerships.

timothysykes.com3 min
OCT 19
$RXRXHighAI 8/10

RXRX Stock Pops As Sanofi Deal, ARK Buying Ignite Momentum

Recursion Pharmaceuticals (RXRX) stock rose 3.85% on news of a Sanofi partnership and ARK Investment's purchases. The company reported positive clinical data for REC-4881 and REC-1245, and raised $200M in equity. RXRX has a strong cash position and a runway into 2029, but remains unprofitable with negative margins.

stockstotrade.com3 min
OCT 16
$RXRXHighAI 9/10

Key facts: RXRX REC-4881 strong efficacy, clean safety; Runway into 2029

Recursion (RXRX) reported positive results from its Phase 1b/2 trial of REC-4881, showing an 87% mean reduction in GI polyp burden and a 92% reduction in upper GI. The drug demonstrated a favorable safety profile, with no treatment-related adverse events above Grade 3. The company plans a registrational trial in H2 2027, pending FDA discussions. Recursion had $561M in cash as of Sept 30, 2026, and expects $200M from a recent offering, extending its runway into 2029.

tradingview.com1 min
OCT 15
$RXRXMed

Recursion (RXRX) Enters New Growth Phase as Sanofi Kicks Off Drug Collab, Shares Soar

Recursion Pharmaceuticals (RXRX) shares surged 17.9% after Sanofi initiated development of drug molecules, triggering a $10M milestone payment, totaling $144M received. RXRX may earn over $300M more in milestones and royalties if approved. The collaboration, started in 2022, focuses on AI-enabled small molecule therapies in immunology and oncology. Hedge fund holdings in RXRX increased 16% QoQ to $287.9M, despite a drop in the number of funds invested.

insidermonkey.com2 min